Multiply Relapsed HCL Patients:
If you're a multiply relapsed HCL patient looking for a non-chemotherapy treatment, consider the Moxe clinical trial at NIH. This is a Phase 3 trial.
Results from the Phase 1 trial indicate there is no toxicity, a complete remission rate of 57%, and a majority of those patients were able to eliminate all signs of malignancy. These results are superior to many other non-chemotherapy treatments for relapsed HCL. Check out the webpage or call Dr. Kreitman at 301-648-7375.
Here's a great link for patients that explains the trial and how the drug works.
"Moxetumomab is a nonchemotherapy treatment that can produce MRD-negative complete remissions where patients have a chance to be free of disease for a long duration," he explained. "We have patients who have been free of MRD for more than 5 years now on moxetumomab, and more than 10 years on the parent drug, BL22."
Here's a link to the clinical trial protocol details.
This referral letter explains the trial to doctors looking for treatment options for their multiply relapsed and refractory HCL patients.
If you're a multiply relapsed HCL patient looking for a non-chemotherapy treatment, consider the Moxe clinical trial at NIH. This is a Phase 3 trial.
Results from the Phase 1 trial indicate there is no toxicity, a complete remission rate of 57%, and a majority of those patients were able to eliminate all signs of malignancy. These results are superior to many other non-chemotherapy treatments for relapsed HCL. Check out the webpage or call Dr. Kreitman at 301-648-7375.
Here's a great link for patients that explains the trial and how the drug works.
"Moxetumomab is a nonchemotherapy treatment that can produce MRD-negative complete remissions where patients have a chance to be free of disease for a long duration," he explained. "We have patients who have been free of MRD for more than 5 years now on moxetumomab, and more than 10 years on the parent drug, BL22."
Here's a link to the clinical trial protocol details.
This referral letter explains the trial to doctors looking for treatment options for their multiply relapsed and refractory HCL patients.
Many thanks for the exciting blog posting! I really enjoyed reading it, you are a brilliant writer. I actually added your blog to my favorites and will look forward for more updates. Great Job, Keep it up..
ReplyDeletenow foods hcl